IBD Therapy Infliximab Tested in Pediatric Patients 7 and Under

IBD Therapy Infliximab Tested in Pediatric Patients 7 and Under
InfliximabA recent study entitled “Infliximab therapy in pediatric patients 7 years of age and younger” reports that infliximab therapy is less efficient in treating inflammatory bowel disease in children aged less than 7 years old when compared to its effect in older children. The study was published in the Journal of Pediatric Gastroenterology & Nutrition. Inflammatory bowel disease consists of a group of autoimmune diseases characterized by dysregulated immune response against the colon and small intestine. The two main types of inflammatory bowel disease are ulcerative colitis and Crohn's disease, with the first being limited to the colon while Crohn's disease can affect the entire gastrointestinal tract (from mouth to anus). Inflammatory bowel disease is estimated to affect approximately 1 million Americans, and usually occurs in young people (from 10 years old to older age). However, young children (less than 7 years old) have also been reported to suffer from inflammatory bowel disease. Since therapeutics for inflammatory bowel disease are usually tested in older children, in this study the authors tested whether  infliximab therapy, which is capable of maintaining disease remission in young children with mild or severe inflammatory bowel disease, is equally effective when administered to
Subscribe or to access all post and page content.